Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04835805 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.
A Phase 1 study of Melanoma, sponsored by Genentech.
- Active
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
- 17
- Study locations
NCT04835805: Active Phase 1 study of Melanoma, sponsored by Genentech.
NCT04835805 is a Phase 1 study of Melanoma that is active but no longer recruiting, run by Genentech. The registered enrollment target is 65 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (91% lower). The trial reports 17 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04835805, a Phase 1 study of Melanoma, is active but no longer recruiting, sponsored by Genentech.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
- 17
- Study locations
Study Summary
This study will evaluate the safety, pharmacokinetics, and activity of belvarafenib as a single agent and in combination with either cobimetinib or cobimetinib plus nivolumab in patients with NRAS-mutant advanced melanoma who have received anti-PD-1/PD-L1 therapy.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Cobimetinib
- DRUG Belvarafenib
Study Locations (17)
Other
- Charité - Universitätsmedizin Berlin - Berlin
- Universitätsklinikum Hamburg-Eppendorf - Hamburg
- Klinikum Mannheim GmbH Universitätsklinikum - Mannheim
- Universitatsklinikum Tubingen - Tübingen
- Universitätsklinikum Würzburg - Würzburg
- Asan Medical Center - PPDS - Seoul
California
- California Pacific Medical Center Research Institute - San Francisco
- UCSF Helen Diller Family CCC - San Francisco
Ontario
- Ottawa Hospital Regional Cancer Centre - Ottawa
- Princess Margaret Hospital - Toronto
Colorado
- University of Colorado Cancer Center - Aurora
Maryland
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center - Baltimore
Missouri
- Washington University School of Medicine - St Louis
New York
- Memorial Sloan Kettering - New York
New South Wales
- Calvary Mater Newcastle - Waratah
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2021-05-13 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 1 |
What the registry record for NCT04835805 still lists
NCT04835805 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.
NCT04835805 lists 17 locations in 10 states (Other, California, Ontario).
Frequently Asked Questions
What is clinical trial NCT04835805 about?
NCT04835805 is a clinical study titled "A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.". This study will evaluate the safety, pharmacokinetics, and activity of belvarafenib as a single agent and in combination with either cobimetinib or cobimetinib plus nivolumab in patients with NRAS-mutant advanced melanoma who have received anti-PD-1/PD-L1 therapy.
What is the current status of trial NCT04835805?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2021-05-13. Estimated completion is 2027-06-30.
What conditions does trial NCT04835805 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT04835805?
The interventions under investigation include: Nivolumab (DRUG), Cobimetinib (DRUG), Belvarafenib (DRUG).
Who is sponsoring clinical trial NCT04835805?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04835805 being conducted?
This trial has 17 study locations across California, Colorado, Maryland, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04835805's enrollment target sits among peer trials
65 145th of 266 higher than 121 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI